ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.
Allermi's $3.5 million seed funding was led by Nelstone Ventures and included participation from FourSight Capital Partners. The company will use the money to expand nationally.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Based in San Francisco, Allermi aims to create a national market for a customizable approach to allergy relief pioneered by a California doctor.
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
Julia Cheek, EverlyWell CEO and cofounder, said in an email that the funding will help the company expand its suite of tests, hire key leadership positions, launch new partnerships and enhance product features this year.
Rising rates of allergies worldwide will cause the global market for allergy diagnostics to nearly triple from $1.3 billion in 2015 to $3.8 billion in 2024, says a new report.
From immunotherapies to mobile health apps, here's how biotech and medtech companies are responding to the rising number of children with food allergies.
There must be some better, more efficient solutions for the essential use of the EpiPen, and Windgap Medical is working on it.
Drug developer Abbott Laboratories is poised to make a $25 billion bid for medical device maker St Jude Medical, allergy free parks could be a thing in the future.
Microbiologist Jason Tetro explains that the best way to protect your child against allergies is to let them get dirty.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
As allergies rise, so does the need for on-the-spot epinephrine treatment. Windgap Medical wants to win a chunk of this fast-growing, $1.3 billion market.
Tech entrepreneur Sean Parker just pledged $24 million to Stanford University to set up a new institute for allergy research, and it comes at an important time: We might not be too far, he says, from finding a treatment that’s curative. The new center will be called the Sean N. Parker Center for Allergy Research. It joins a […]
http://www.youtube.com/watch?v=xxdf7MCv8mk Nietzsche may have been thinking of emotional turmoil when he wrote “That which does not kill us makes us stronger,” but the quote could just as easily apply to a potential life science innovation — a cure for peanut allergies. Scientists testing a treatment on children have had positive results from the most unlikely […]
A new smartphone biosensor may provide particularly helpful point-of-care possibilities for medicine in remote locations and developing nations. Researchers at the University of Illinois, Urbana-Champaign are developing a smartphone app plus cradle device that can take food samples and determine whether they have toxins or allergens. It can also detect bacteria and contaminated water, according to […]
